EUVIMEDEUVIMED entdecken
Crossref

Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy

Hao Wu, Xinshuang Wang, Jing Yu, Jiao Li, Zhenhua Ma, Xi Sheng, Han Yang, Liping Wei, Xin Qi

The Journal of Gene Medicine · 2024

DOI: 10.1002/jgm.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Hao Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: MicroRNAs, Cardiomegaly, RNA, Long Noncoding, Receptor, Transforming Growth Factor-beta Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Tianjin Health Research Project, National Natural Science Foundation of China, Project of Tianjin Municipal Health Commission on TCM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study aimed to analyze differentially expressed lncRNAs in a model of cardiac hypertrophy, specially focusing on the molecular mechanisms of lncRNA NONMMUT023529 (lncRNA N29) in myocardial hypertrophy. Based on gene microarray results, RT‐ q PCR validation confirmed that lncRNA N29 was significantly upregulated in TAC‐induced mice cardiac tissues. Echocardiographic assessments further verified that silencing lncRNA N29 led to a marked improvement in cardiac function, which aligned with the pathological findings revealed by H&E and Masson staining. Meanwhile, immunofluorescence staining results also confirmed that silencing lncRNA N29 effectively inhibited myocardial hypertrophy. Dual luciferase reporter assay and western blot results confirmed that lncRNA can mediate miR‐193b‐5p/TGFBR2 axis to regulate smad/2/3 expression and mitigate the progression of myocardial hypertrophy. Our findings suggested that the close association between the protective mechanism involving in the silencing lncRNA N29 in myocardial hypertrophy and miR‐193b‐5p/TGFBR2 axis. We identified that lncRNA N29 might act as a therapeutic target for the treatment of myocardial hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCardiomegalyRNA, Long NoncodingReceptor, Transforming Growth Factor-beta Type IIGene SilencingAnimalsMiceDisease Models, AnimalGene Expression RegulationMaleDisease ProgressionSignal TransductionMice, Inbred C57BLHumans

Stichwörter der Autor:innen

TGFBR2cardiac hypertrophylncRNA NONMMUT023529miR‐193b‐5psmad2/3

Substanzen

MicroRNAsRNA, Long NoncodingReceptor, Transforming Growth Factor-beta Type IIMIRN193 microRNA, mouse

Autor:innen und Institutionen

  • School of Medicine, Nankai University, Tianjin, China.
  • Department of Cardiology, Tianjin Union Medical Center, Tianjin, China.
  • Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.

Förderung

  • Tianjin Health Research Project
  • National Natural Science Foundation of China
  • Project of Tianjin Municipal Health Commission on TCM

Zitieren

APA

Wu, H., Wang, X., Yu, J., Li, J., Ma, Z., Sheng, X., Yang, H., Wei, L., & Qi, X. (2024). Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.70002

Vancouver

Wu H, Wang X, Yu J, Li J, Ma Z, Sheng X, et al. Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.70002

BibTeX
@article{Wu2024,
  author = {Wu, Hao and Wang, Xinshuang and Yu, Jing and Li, Jiao and Ma, Zhenhua and Sheng, Xi and Yang, Han and Wei, Liping and Qi, Xin},
  title = {Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy},
  journal = {The Journal of Gene Medicine},
  year = {2024},
  doi = {10.1002/jgm.70002}
}
Kostenlos starten →